The information on this page applies only to the United States
Valeant’s U.S. dermatology business continues to be a key strength and our growth further solidifies our position as a significant player in this therapeutic area. Not only does dermatology have what we believe is an attractive risk and reward profile, we believe there's room for a focused, smaller company like Valeant and we are working to build a significant U.S. dermatology portfolio through both acquisitions and internal growth. Our dermatology products help patients who are suffering from actinic keratoses, acne, psoriasis and those who are looking for a reduction in the appearance of scars, skin-aging and apparent pigmentation.
Our U.S. Dermatology segment’s principle dermatology products include: Zovirax®
and Retin-A Micro®